In the heart and beyond: Mitochondrial dysfunction in heart failure with preserved ejection fraction (HFpEF)
-
Published:2024-06
Issue:
Volume:76
Page:102461
-
ISSN:1471-4892
-
Container-title:Current Opinion in Pharmacology
-
language:en
-
Short-container-title:Current Opinion in Pharmacology
Author:
Bhattarai Nisha,
Scott IainORCID
Reference30 articles.
1. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic;Redfield;JAMA,2003
2. Heart failure with preserved, Borderline, and reduced ejection fraction: 5-year outcomes;Shah;J Am Coll Cardiol,2017
3. Cardiac energy metabolism in heart failure;Lopaschuk;Circ Res,2021
4. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management;Gevaert;Heart,2022
5. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015